Other immunohistochemical markers downstream of EGFR signaling pathways such as pAKT, pERK (also known as pMAPK), or pSTAT3 could potentially be more useful as prognostic markers and might also help to stratify ovarian cancer patient populations for treatment with TKIs [59]. Here, EGFR is linked to ovarian carcinoma.